This is a spontaneous report from a contactable consumer. A Black male patient of an unspecified age started to 
receive gabapentin, oral from 2007 to 2008 at maximum dose, 3x/day for fibromyalgia, verapamil hydrochloride 
(COVERA), via an unspecified route of administration from an unspecified date to an unspecified date at an 
unspecified dose for angina pectoris.  The patient medical history was not reported.  The patient's concomitant 
medications were not reported.  The patient reported that gabapentin was first prescribed for his pain when he was 
diagnosed with fibromyalgia. The patient stated that COVERA had synergistic effect with gabapentin.  The action 
taken in response to the events for gabapentin and for verapamil hydrochloride was unknown. The outcome of the 
events was unknown. 
Pfizer is Marketing Authorization Holder of gabapentin in the reporter's country. This may be a duplicate report in 
Print Time: 14-JAN-2016 11:54 AM If a field is blank, there is no data for that field Page 8 of 20
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
situations where another Marketing Authorization Holder of gabapentin has submitted the same report to the 
regulatory authorities.